Polypill Cost-Effectiveness Estimates for a Population of 1 Million Adults at Varying Levels of Risk for CVD Treated for 10 Years in India | Absolute risk of a CVD event over 10 years |
| Costs and effects | Comparison with no polypill | > 35 percent | > 25 percent | > 15 percent | > 5 percent |
| Total cost (2001 US$ millions) | 23.5 | 34.5 | 51.4 | 92.2 | 205.2 |
| Profile of total costs |
| Percentage attributable to inpatient stay | 12.0 | 6.0 | 3.0 | 1.0 | 0.3 |
| Percentage attributable to ambulatory care | 0 | 29.0 | 40.0 | 49.0 | 54.0 |
| Percentage attributable to labor | 75.0 | 36.0 | 21.0 | 9.0 | 2.0 |
| Percentage attributable to pharmaceuticals | 0 | 23.0 | 31.0 | 38.0 | 42.0 |
| Percentage attributable to laboratory expenses | 12.0 | 6.0 | 3.0 | 1.0 | 0.0 |
| Effects a |
| Number of myocardial infarction cases averted | n.a. | 10,200 | 14,400 | 21,300 | 31,800 |
| Number of stroke cases averted | n.a. | 5,200 | 7,000 | 12,400 | 19,600 |
| Number of coronary heart disease deaths averted | n.a. | 10,500 | 13,500 | 19,600 | 25,900 |
| Number of stroke deaths averted | n.a. | 5,900 | 7,500 | 10,500 | 14,200 |
| Number of life years saved | n.a. | 39,000 | 51,000 | 67,000 | 98,000 |
| Number of DALYs gained | n.a. | 41,000 | 57,000 | 86,000 | 134,000 |
| Incremental cost-effectiveness (US$/DALY) | n.a. | 300 | 990 | 1,500 | 2,430 |
Source: Authors' calculations.
n.a. = not applicable.
a. Each strategy compared with no polypill.
